<DOC>
	<DOCNO>NCT01984294</DOCNO>
	<brief_summary>This study evaluate antiviral efficacy ledipasvir/sofosbuvir ( LDV/SOF ) fixed-dose combination ( FDC ) plus ribavirin ( RBV ) LDV/SOF plus GS-9669 treatment-naive treatment-experienced participant chronic genotype 1 hepatitis C virus ( HCV ) infection . A total 90 participant plan enrol study 8 week treatment , approximately 60 prior treatment regimen contain pegylated interferon ( PEG ) RBV ≥ 12 week . Randomization stratify treatment-naive versus treatment-experienced HCV genotype ( 1a versus 1b ) .</brief_summary>
	<brief_title>Ledipasvir/Sofosbuvir Fixed-Dose Combination With Ribavirin GS-9669 Subjects With Chronic Genotype 1 HCV Infection</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Sofosbuvir</mesh_term>
	<mesh_term>Ledipasvir</mesh_term>
	<mesh_term>Ledipasvir , sofosbuvir drug combination</mesh_term>
	<criteria>Age ≥ 18 , chronic genotype 1 HCV infection Documented HCV treatmentnaïve treatmentexperienced subject fail previous PEG+RBV regimen HCV RNA &gt; 10,000 IU/mL Screening Presence compensate cirrhosis Screening laboratory value within define threshold Use two effective contraception method female childbearing potential sexually active male Pregnant nursing female male pregnant female partner Coinfection HIV hepatitis B virus ( HBV ) Current prior history clinical hepatic decompensation Chronic use systemic immunosuppressive agent History clinically significant illness medical disorder may interfere subject treatment , assessment compliance protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>HCV genotype 1</keyword>
	<keyword>HCV</keyword>
	<keyword>Sustained Virologic Response</keyword>
	<keyword>Direct-Acting Antiviral</keyword>
	<keyword>Combination Therapy</keyword>
	<keyword>GS-7977</keyword>
	<keyword>GS-5885</keyword>
	<keyword>Ribavirin</keyword>
	<keyword>Open Label</keyword>
	<keyword>Sofosbuvir</keyword>
	<keyword>Treatment-Naive</keyword>
	<keyword>Protease Inhibitors</keyword>
	<keyword>PI</keyword>
	<keyword>Treatment experience</keyword>
	<keyword>Cirrhotic</keyword>
</DOC>